Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Lewis

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
The Journal of Investigative Dermatology|November 13, 2016
FISH Panel for Leukemic CTCLJason Weed, Juliet Gibson, Julia Lewis, et al.
Statistics in Medicine|July 25, 2019
Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney diseaseEdward Vonesh, Hocine Tighiouart, Jian Ying, et al.
Drugs in R&D|August 5, 2015
Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial DataRoger A Rodby, Kausik Umanath, Robert Niecestro, et al.
Journal of the American Society of Nephrology : JASN|July 24, 2010
Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosisTahira P Alves, Xuelei Wang, Jackson T Wright, et al.
The Journal of Experimental Medicine|April 3, 2002
Resident skin-specific gammadelta T cells provide local, nonredundant regulation of cutaneous inflammationMichael Girardi, Julia Lewis, Earl Glusac, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 27, 2009
Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definitionNicholas Stoycheff, Lesley A Stevens, Christopher H Schmid, et al.
Nephron. Clinical Practice|October 19, 2012
The safety and tolerability of ferric citrate as a phosphate binder in dialysis patientsMarvin Sinsakul, Mohammed Sika, Mark Koury, et al.
Nephrology (Carlton, Vic.)|March 20, 2013
Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockersSara E Ivory, David K Packham, Anne T Reutens, et al.
Epilepsia Open|June 9, 2018
Secular changes in severity of intellectual disability in tuberous sclerosis complex: A reflection of improved identification and treatment of epileptic spasms?Charlotte Tye, Laura E Thomas, Julian R Sampson, et al.
The Journal of Experimental Medicine|September 4, 2003
The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancerMichael Girardi, Earl Glusac, Renata B Filler, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
The Journal of Investigative Dermatology|November 13, 2016
FISH Panel for Leukemic CTCLJason Weed, Juliet Gibson, Julia Lewis, et al.
Statistics in Medicine|July 25, 2019
Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney diseaseEdward Vonesh, Hocine Tighiouart, Jian Ying, et al.
Drugs in R&D|August 5, 2015
Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial DataRoger A Rodby, Kausik Umanath, Robert Niecestro, et al.
Journal of the American Society of Nephrology : JASN|July 24, 2010
Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosisTahira P Alves, Xuelei Wang, Jackson T Wright, et al.
The Journal of Experimental Medicine|April 3, 2002
Resident skin-specific gammadelta T cells provide local, nonredundant regulation of cutaneous inflammationMichael Girardi, Julia Lewis, Earl Glusac, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 27, 2009
Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definitionNicholas Stoycheff, Lesley A Stevens, Christopher H Schmid, et al.
Nephron. Clinical Practice|October 19, 2012
The safety and tolerability of ferric citrate as a phosphate binder in dialysis patientsMarvin Sinsakul, Mohammed Sika, Mark Koury, et al.
Nephrology (Carlton, Vic.)|March 20, 2013
Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockersSara E Ivory, David K Packham, Anne T Reutens, et al.
Epilepsia Open|June 9, 2018
Secular changes in severity of intellectual disability in tuberous sclerosis complex: A reflection of improved identification and treatment of epileptic spasms?Charlotte Tye, Laura E Thomas, Julian R Sampson, et al.
The Journal of Experimental Medicine|September 4, 2003
The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancerMichael Girardi, Earl Glusac, Renata B Filler, et al.
Pageof 6